Understanding immunotherapy response in endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at why some people with endometrial cancer respond well to immunotherapy. It uses samples of your tumor to help doctors better understand how to choose the right treatment for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced or recurrent endometrial cancer (including carcinosarcoma).
- You have never taken an immunotherapy drug for your cancer.
- You are willing to provide fresh and preserved tumor samples for testing.
- You agree to take part in this research study.
- You do not have HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well immunotherapy works for advanced endometrial and cervical cancer by checking certain markers in your blood and tumor. It aims to find out which patients benefit most from this treatment.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) for patients with a specific type of endometrial cancer that has a high number of gene mutations (called dMMR or MSI-H). The goal is to shrink or eliminate the tumor so surgery may not be needed.
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.